文献速递贫血与红细胞疾病

羟基脲降低镰状细胞贫血患儿经颅多普勒流速:EXTEND试验

Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
PubMed 文献 · Br J Haematol · 2021-07-22

EXTEND试验评估羟基脲对牙买加镰状细胞贫血患儿经颅多普勒(TCD)流速的影响。

要点

  • 羟基脲可显著降低高TCD流速镰状细胞贫血患儿的最大TAMV。
  • 无卒中史患儿卒中风险降低,有卒中史者卒中仍较多。
  • 在无输血管理资源有限地区,羟基脲至最大耐受剂量可行且有益。

核心结论

  • 在无输血支持的低资源地区,羟基脲滴定至最大耐受剂量可降低镰状细胞贫血患儿TCD流速并减少无原发性卒中史患儿的卒中风险。

研究设计与样本

  • 患儿按治疗状态和卒中史分为三组:组1无卒中史且在用羟基脲(n=12);组2无卒中史未用羟基脲(n=21);组3有卒中史未用羟基脲(n=10)。

主要发现

  • 无临床卒中的患儿脑MRI/MRA保持稳定。

关键数值与推荐

  • 基线最大TAMV≥170 cm/s为纳入标准。

临床怎么用

  • 对TCD流速升高的镰状细胞贫血患儿,可考虑羟基脲滴定至最大耐受剂量以降低TCD流速。
  • 在无输血管理条件下,羟基脲可作为降低卒中风险的可行策略,尤其适用于无卒中史患儿。

局限性

  • 研究在无输血管理的低资源地区进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

EXpanding Treatment for Existing Neurological Disease (EXTEND) investigated whether hydroxycarbamide lowers transcranial Doppler (TCD) velocities in Jamaican children with sickle cell anaemia (SCA) and elevated TCD velocity with or without previous stroke. Forty-three children (age 2-17 years) with baseline maximum time-averaged mean velocity (TAMV) ≥ 170 cm/s were stratified into three risk categories based on treatment status and stroke history: Group 1 (no history of stroke, on hydroxycarbamide, n = 12); and Groups 2 (no stroke, no hydroxycarbamide, n = 21) and 3 (previous stroke, no hydroxycarbamide, n = 10). Open-label hydroxycarbamide at 20 mg/kg/day was commenced, with escalation to maximum tolerated dose (MTD) based on mild marrow suppression (average dose 25·4 ± 4·5 mg/kg/day). TCD was performed every six months with brain magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA) at baseline and after 18-months of hydroxycarbamide. The maximum TAMV decreased significantly compared to baseline (24 ± 30 cm/s, P < 0·0001), with similar declines in all groups. Clinical stroke occurred in five children, one in Group 1, none in Group 2, and four in Group 3, P = 0·0032, comparing group incidence rates. Brain MRI/MRA was stable in children without clinical stroke. EXTEND documents the feasibility and benefits of hydroxycarbamide at MTD to lower TCD velocities and reduce stroke risk in children with SCA and no history of primary stroke in low-resource settings without transfusion management.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rankine-Mullings A, Reid M, Soares D, et al. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. Br J Haematol. 2021. PMID: 34291449. doi:10.1111/bjh.17698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。